BioCryst Pharmaceuticals ... (BCRX)
9.38
-0.01 (-0.11%)
At close: Feb 20, 2025, 3:59 PM
9.39
0.11%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 9.3 |
| Market Cap | 1.94B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.61 |
| PE Ratio (ttm) | -15.38 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.5 |
| Volume | 3,053,490 |
| Avg. Volume (20D) | 2,358,142 |
| Open | 9.39 |
| Previous Close | 9.39 |
| Day's Range | 9.30 - 9.50 |
| 52-Week Range | 4.03 - 9.50 |
| Beta | undefined |
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 4, 1994
Employees 536
Stock Exchange NASDAQ
Ticker Symbol BCRX
Website https://www.biocryst.com
Analyst Forecast
According to 6 analyst ratings, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 27.93% from the latest price.
Buy 83.33%
Hold 16.67%
Sell 0.00%
Next Earnings Release
BioCryst Pharmaceuticals Inc. is scheduled to release its earnings on Feb 24, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-12.81%
BioCryst Pharma shares are trading lower following...
Unlock content with
Pro Subscription
6 months ago
+6.98%
BioCryst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results. Additionally, the company raised its FY24 Orladeyo revenue guidance above estimates.
